Myriad Genetics, Inc.
General ticker "MYGN" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $538.4M (TTM average)
Myriad Genetics, Inc. does not follow the US Stock Market performance with the rate: -3.7%.
Estimated limits based on current volatility of 2.4%: low 5.96$, high 6.25$
Factors to consider:
- Total employees count: 2700 (0.0%) as of 2025
- US accounted for 38.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Strategic risks and growth management, Payment issues, Liquidity and credit risks, Litigation risks
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.22$, 11.56$]
- 2026-12-31 to 2027-12-31 estimated range: [5.94$, 12.56$]
Financial Metrics affecting the MYGN estimates:
- Positive: with PPE of -93.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Positive: 42.57 < Shareholder equity ratio, % of 52.08 <= 64.23
- Positive: Inventory ratio change, % of 0.40 <= 0.80
- Positive: Industry inventory ratio change (median), % of 0.10 <= 0.28
- Positive: -0.03 < Operating cash flow per share per price, % of 0.30
Short-term MYGN quotes
Long-term MYGN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $753.20MM | $837.60MM | $824.50MM |
| Operating Expenses | $1,010.60MM | $961.10MM | $1,211.70MM |
| Operating Income | $-257.40MM | $-123.50MM | $-387.20MM |
| Non-Operating Income | $-4.80MM | $0.00MM | $-7.90MM |
| Interest Expense | $2.90MM | $2.80MM | $10.50MM |
| R&D Expense | $88.70MM | $113.40MM | $106.80MM |
| Income(Loss) | $-262.20MM | $-123.50MM | $-395.10MM |
| Taxes | $1.10MM | $3.80MM | $-29.20MM |
| Net Income(Loss)* | $-263.30MM | $-127.30MM | $-365.90MM |
| Stockholders Equity | $783.20MM | $701.10MM | $368.00MM |
| Inventory | $22.00MM | $27.50MM | $30.60MM |
| Assets | $1,146.50MM | $1,027.60MM | $706.60MM |
| Operating Cash Flow | $-110.90MM | $-8.70MM | $1.80MM |
| Capital expenditure | $73.30MM | $29.70MM | $27.40MM |
| Investing Cash Flow | $31.90MM | $-11.90MM | $-27.40MM |
| Financing Cash Flow | $152.90MM | $-7.40MM | $64.20MM |
| Earnings Per Share** | $-3.18 | $-1.41 | $-3.92 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.